<code id='9590A9A976'></code><style id='9590A9A976'></style>
    • <acronym id='9590A9A976'></acronym>
      <center id='9590A9A976'><center id='9590A9A976'><tfoot id='9590A9A976'></tfoot></center><abbr id='9590A9A976'><dir id='9590A9A976'><tfoot id='9590A9A976'></tfoot><noframes id='9590A9A976'>

    • <optgroup id='9590A9A976'><strike id='9590A9A976'><sup id='9590A9A976'></sup></strike><code id='9590A9A976'></code></optgroup>
        1. <b id='9590A9A976'><label id='9590A9A976'><select id='9590A9A976'><dt id='9590A9A976'><span id='9590A9A976'></span></dt></select></label></b><u id='9590A9A976'></u>
          <i id='9590A9A976'><strike id='9590A9A976'><tt id='9590A9A976'><pre id='9590A9A976'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          explore

          author:explore    - browse:916
          Franklin faces
          Adobe

          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

          advertisement

          Arch declined to comment on the new fundraising.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore